Collecting blood samples from heart attack patients to identify new biomarkers
Official title: The Harefield Acute Myocardial Infarction Cohort
Run by Royal Brompton & Harefield NHS Foundation Trust · NCT04218344 · Data updated 2026-11-12
This study is collecting blood samples from heart attack patients during routine procedures to see if they can find new markers that help us understand heart disease better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Locations | 2 sites (Harefield, Middlesex and 1 other locations) |
| Status | Recruiting |
| Started | January 9, 2020 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2035 |
| Registry record updated | January 18, 2020 |
| Trial ID | NCT04218344 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients presenting with ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina, and other related conditions undergoing coronary angiography.
✕Probably not a fit
Patients who do not provide informed consent or those who do not survive the hospital episode may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to gather blood samples during routine angiogram procedures from patients who have experienced acute coronary syndromes, such as heart attacks. The collected data will include clinical parameters from ECGs, echocardiograms, and MRI scans, which will be analyzed to identify novel biomarkers related to inflammation and micro-organism activity. Follow-up data will be collected through questionnaires at 6 weeks and 6 months post-procedure, with additional updates via phone at one year. The goal is to enhance understanding of heart disease causes and improve treatment strategies.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment strategies for patients with acute coronary syndromes.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for heart disease, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • All patients presenting to Harefield Hospital through the Primary Percutaneous Coronary Intervention programme, with ST-segment elevation myocardial infarction, non ST-segment elevation myocardial infarction, unstable angina, Tako Tsubo syndrome, spontaneous coronary artery dissection and acute myocarditis, with the intention to assess with coronary angiography. Exclusion Criteria: * Patients will be able to self-exclude if they do not provide full informed consent * Every effort will be made to obtain informed consent from all patients. * Patients who do not survive the hospital episode will undergo a Professional or Personal Consultee process of assumed consent.
Where it's running
-
Harefield Hospital
Harefield, Middlesex, United Kingdom Recruiting -
Royal Brompton and Harefield NHS Foundation Trust
Uxbridge, Middlesex, United Kingdom Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
-
Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure
This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.
-
Digital lifestyle platform after rehabilitation to support self-management
A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.
-
AI-driven Medipixel fractional flow reserve to guide PCI
This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.
-
Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions
This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.
-
AI-assisted interpretation of chest pain CT in the emergency department
A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.